What Goserelin is
Goserelin is a GnRH agonist peptide analog used in approved endocrine and oncology-related contexts.
Goserelin is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it is another clear example of peptide analogs being real high-consequence medicines.
The useful starting point is to separate the molecule itself from the internet story around it. It is another clear example of peptide analogs being real high-consequence medicines.
Why people keep looking it up
It is another clear example of peptide analogs being real high-consequence medicines.
Goserelin is a GnRH agonist peptide analog used in approved endocrine and oncology-related contexts.
Goserelin tends to stay in the conversation because it touches a familiar public theme: gnrh agonist, hormone suppression, and endocrine medicine. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide analog with direct human evidence and clear regulatory context.
Human trials and labeling support specific approved uses.
Mechanistic support follows GnRH receptor pharmacology and endocrine suppression biology.
Why this page carries the current tier: Approved peptide analog with direct human evidence and clear regulatory context.
The current seed trail for Goserelin is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This class carries major endocrine effects and should not be framed like an optimization peptide.
FDA-approved goserelin products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Goserelin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Goserelin is CID 5311128. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 5311128
- Formula
- C59H84N18O14
- Molecular weight
- 1269.4
- InChIKey
- BLCLNMBMMGCOAS-URPVMXJPSA-N
Matched synonyms include goserelin, 65807-02-5, Decapeptide I, Goserelina, Gosereline, Goserelinum, ICI-118630, ICI 118630.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Goserelin returns 400 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Goserelin returns 2180 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- ZOLADEX
- Generic names
- GOSERELIN
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA019726
Indications and usage. 1 INDICATIONS AND USAGE ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Women of Childbearing Potential and Pregnancy: Pregnancy must be excluded for use in benign gynecological conditions. Women should avoid pregnancy ( 5.1 ) Tumor Flare Phenomenon: Transient worsening of tumor symptoms may occur during the first few weeks of treatment with ZOLADEX, which may include ureteral obstruction and spinal cord compression. Monitor patients at risk for complications...
Contraindications. 4 CONTRAINDICATIONS Hypersensitivity ( 4.1 ) Pregnancy unless used for treatment of advanced breast cancer ( 4.2 ) 4.1 Hypersensitivity Anaphylactic reactions to ZOLADEX have been reported in the medical literature. ZOLADEX is contraindicated in those patients who have a known hypersensitivity to GnRH, GnRH agonist analogues or any of the components in ZOLADEX [see Warnings and Precautions ( 5.6 )]. 4.2 Pregnancy ZO...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.